Investor Center


Press Releases

There are currently no events to display.
Date Title  
Toggle Summary Bellicum Pharmaceuticals to Participate in Two Healthcare Investor Conferences in September
HOUSTON , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that senior management will participate in two upcoming healthcare
Toggle Summary Bellicum Pharmaceuticals Reports Second Quarter 2018 Financial Results
Management to host conference call and webcast today at 5 p.m. Eastern HOUSTON , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported
Toggle Summary Bellicum Pharmaceuticals Appoints Dr. Thierry Darcis as General Manager of Europe to Lead the Anticipated Launch of BPX-501
HOUSTON , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of Thierry Darcis , M.D., M.B.A.
Toggle Summary Bellicum Pharmaceuticals to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018
HOUSTON , July 31, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company will host a conference call and live webcast on Tuesday,
Toggle Summary Bellicum Pharmaceuticals Announces Departure of Chief Financial Officer
HOUSTON , July 16, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Alan Musso , Chief Financial Officer, will be leaving the Company
Toggle Summary Bellicum Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
HOUSTON , May 30, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a corporate
Toggle Summary Bellicum Pharmaceuticals Appoints Shane Ward as General Counsel
HOUSTON , May 29, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of Shane M. Ward as General Counsel and Corporate Secretary.
Toggle Summary Bellicum Announces Clinical Presentations on Lead Product Candidate BPX-501 at the 23rd Congress of the European Hematology Association
Oral and poster presentations highlight BPX-501 data in pediatric patients with PIDs and AML HOUSTON , May 17, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood
Toggle Summary Bellicum Announces Oral Presentation on Dual-Switch CAR-T Technology at the 21st Annual Meeting of the American Society of Gene and Cell Therapy
HOUSTON , May 15, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that data from preclinical studies of its HER2-targeted CAR-T cell
Toggle Summary Bellicum Pharmaceuticals Reports First Quarter 2018 Financial Results
HOUSTON , May 08, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the first quarter ended March 31, 2018, and provided
Toggle Summary Bellicum Pharmaceuticals Announces Closing of Public Offering
HOUSTON , April 20, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the closing of its previously
Toggle Summary Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock
HOUSTON , April 17, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the pricing of an underwritten
Toggle Summary Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock
HOUSTON , April 16, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that it has commenced an
Toggle Summary Bellicum Announces Clinical Hold Lifted on U.S. Studies of BPX-501
HOUSTON , April 11, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the U.S. Food and Drug Administration has lifted the clinical hold
Toggle Summary Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2017
Recruitment completed in European BP-004 registration trial of BPX-501 and rimiducid Positive BPX-501 interim results reported in AML and primary immunodeficiencies GoCAR-T candidate BPX-601 targeting PSCA in pancreatic cancer shows early promise with robust cell expansion in first patient dosed
Toggle Summary Bellicum Announces Interim Results Showing Low Rates of Cancer Recurrence in Pediatric AML Patients Treated with BPX-501
Company also reports encouraging disease-free survival and overall survival rates in pediatric patients with primary immunodeficiencies A pediatric registration trial is being planned HOUSTON , March 13, 2018 (GLOBE NEWSWIRE) --   Bellicum Pharmaceuticals , Inc. (NASDAQ:BLCM), a leader in
Toggle Summary Bellicum Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call and Webcast on March 13, 2018
HOUSTON , March 06, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company will host a conference call and live webcast on Tuesday,
Toggle Summary Bellicum Announces Update on Clinical Hold of U.S. BPX-501 Studies
HOUSTON , Feb. 23, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced it has received notification from the U.S.
Toggle Summary Bellicum Pharmaceuticals Appoints Edmund P. Harrigan, M.D. to its Board of Directors
HOUSTON , Feb. 21, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of Edmund Harrigan , M.D. to its Board of Directors. Dr.
Toggle Summary Bellicum Pharmaceuticals Appoints Dr. William Grossman as Chief Medical Officer
HOUSTON, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of William Grossman, M.D., Ph.D., as Chief Medical Officer,
Toggle Summary Bellicum Pharmaceuticals Announces Clinical Hold on BPX-501 Clinical Trials in the United States
HOUSTON , Jan. 30, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company has received notice from the U.S.
Toggle Summary Bellicum Pharmaceuticals Announces Presentations of its Controllable Switch Technology Platform at the American Society of Hematology 2017 Annual Meeting
Results support technology’s potential to control activation, persistence, and elimination of cell therapies for improved safety and efficacy ATLANTA , Dec. 11, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular
Toggle Summary Bellicum Announces Data Presentation Demonstrating Improved Immune Recovery Following Haploidentical Stem Cell Transplant with BPX-501 in Children with Blood Cancers and Nonmalignant Diseases
112 pediatric patients with a median follow-up of 18 months were reviewed in an oral presentation at the 59th Annual Meeting of the American Society of Hematology ATLANTA , Dec. 09, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (NASDAQ:BLCM), a leader in developing novel, controllable
Toggle Summary Bellicum Pharmaceuticals to Present at the Jefferies 2017 London Healthcare Conference
HOUSTON , Nov. 08, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a corporate
Toggle Summary Bellicum Reports Third Quarter 2017 Financial Results
HOUSTON , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the third quarter ended September 30, 2017, and
Toggle Summary Bellicum Announces Data Presentations on Lead Product Candidate BPX-501 and CAR-T Program at the 59th American Society of Hematology Annual Meeting
Four abstracts accepted, including oral presentation on BPX-501 HOUSTON , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that four
Toggle Summary Bellicum Pharmaceuticals to Present at Three Healthcare Investor Conferences in September
HOUSTON , Aug. 30, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that senior management will present at three upcoming healthcare investor
Toggle Summary Bellicum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
Company updates BPX-501 program Enrollment progressing in early clinical trials of CAR T and TCR product candidates Company to host conference call and webcast on August 8 at 5:00 PM EDT HOUSTON , Aug. 08, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (Nasdaq:BLCM), a leader in
Toggle Summary Bellicum Pharmaceuticals Appoints Gregory Naeve as Chief Business Officer
HOUSTON, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Gregory Naeve, Ph.D., has been appointed as Chief Business Officer,
Toggle Summary Bellicum Pharmaceuticals to Report Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 8, 2017
HOUSTON , Aug. 01, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company will host a conference call and live webcast on Tuesday,
Toggle Summary Bellicum Reports Clinical Results of BPX-501 in Pediatric Leukemias at the 22nd Congress of the European Hematology Association
Oral presentation highlights high success rate of haploidentical transplants, with low incidence of disease relapse and uncontrolled GvHD MADRID, Spain , June 23, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular
Toggle Summary Bellicum Announces Clinical Data on BPX-501 at Presidential Symposium of the 22nd Congress of the European Hematology Association
U.S. and E.U. data suggest favorable outcomes to alternative transplants in patients with hematologic cancers and genetic blood diseases MADRID, Spain , June 23, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular
Toggle Summary Bellicum Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference
HOUSTON , May 31, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a corporate
Toggle Summary Bellicum Announces Clinical Presentations at the 22nd Congress of the European Hematology Association
Overall-cohort abstract on BPX-501 selected for presentation at Presidential Symposium Oral and poster presentations highlight BPX-501 data in leukemias and hemoglobinopathies HOUSTON , May 18, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (Nasdaq:BLCM), a leader in developing novel,
Toggle Summary Bellicum Pharmaceuticals Announces Management Changes
HOUSTON , May 15, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Annemarie Moseley , Ph.D., M.D., the Company’s Chief Operating Officer
Toggle Summary Bellicum Pharmaceuticals Reports First Quarter 2017 Financial Results
HOUSTON , May 08, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the first quarter ended March 31, 2017 and provided an
Toggle Summary Bellicum Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care Conference
HOUSTON , April 26, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a corporate
Toggle Summary Bellicum Pharmaceuticals Announces Late-Breaking Presentation of Dual-Switch CAR-T / TCR Technology at AACR
HOUSTON , April 04, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced two presentations of preclinical results on the Company’s proprietary
Toggle Summary Bellicum Pharmaceuticals Announces Closing of Public Offering
HOUSTON , March 30, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) today announced the closing, on March 29, 2017 , of its previously announced underwritten public offering of 5,750,000 shares of its common stock, including 750,000 shares sold pursuant to the underwriters’
Toggle Summary Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock
HOUSTON , March 23, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $12.00 per share. The aggregate offering size, before deducting the
Toggle Summary Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock
HOUSTON , March 22, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. Bellicum expects to grant the underwriters of the offering a 30-day option to purchase up to an
Toggle Summary Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
On track to complete enrollment in E.U. registration trials for BPX-501 and rimiducid this year Reported updated clinical data with BPX-501 demonstrating rapid immune recovery and low rates of GvHD in children with blood cancers and orphan inherited blood disorders Initiated clinical trials of
Toggle Summary Bellicum Pharmaceuticals to Present at the Barclays Global Healthcare Conference
HOUSTON , March 08, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals , Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a corporate
Toggle Summary Bellicum to Report Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call and Webcast on March 13, 2017
HOUSTON , March 06, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company will host a conference call and live webcast on Monday,
Toggle Summary Bellicum Presents Updated Clinical Results at 2017 BMT Tandem Meetings on BPX-501 in Orphan Inherited Blood Disorders and Hematologic Cancers
Study demonstrates consistent, durable outcomes at six and 12 months with very low incidence of GvHD HOUSTON , Feb. 22, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood
Toggle Summary Bellicum Announces Initiation of Patient Dosing with Controllable CAR T-Cell Product Candidate
BPX-601 being studied in pancreatic cancers expressing PSCA HOUSTON , Feb. 21, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced it has dosed
Toggle Summary Bellicum Announces Appointment of Rick Fair as Chief Executive Officer in Preparation for Commercialization of BPX-501 and Next Phase of Growth
HOUSTON, Jan. 31, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of Rick Fair as
Toggle Summary Adaptimmune and Bellicum Pharmaceuticals Enter a Strategic Collaboration to Evaluate Next-Generation T-Cell Therapies
PHILADELPHIA and OXFORD, United Kingdom and HOUSTON, Dec. 19, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for
Toggle Summary Bellicum Presents Clinical Results to Date of BPX-501 Pediatric Program and Provides Regulatory Update at Investor Event During ASH Annual Meeting
105 patients treated with BPX-501 in BP-004 trial; 85 with more than 100 days of follow-up Company reports encouraging results with BPX-501 in high-risk pediatric leukemia patients SAN DIEGO --(BUSINESS WIRE)--Dec. 5, 2016-- Bellicum Pharmaceuticals, Inc.
Toggle Summary Bellicum Pharmaceuticals Announces GoCAR-T and GoTCR Preclinical Presentations at the American Society of Hematology 2016 Annual Meeting
Results demonstrate unique control of cell proliferation and persistence may improve outcomes in solid tumors SAN DIEGO --(BUSINESS WIRE)--Dec. 5, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular
Toggle Summary Bellicum Announces Updated Clinical Data from BPX-501 Study in Children with Primary Immune Deficiencies and Hemoglobinopathies
35 children with genetic immune disorders and hemoglobinopathies are disease- and GvHD-free following haploidentical stem cell transplant with BPX-501 Webcast of ASH investor/analyst event scheduled for Monday, December 5 at 12:15 p.m. PST SAN DIEGO --(BUSINESS WIRE)--Dec.
Toggle Summary Bellicum Pharmaceuticals Recommended for $16.9 Million Award from the Cancer Prevention and Research Institute of Texas
CPRIT funds would support comparative outcomes clinical trials of BPX-501 in AML patients HOUSTON --(BUSINESS WIRE)--Nov. 16, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for
Toggle Summary Bellicum Reports Third Quarter 2016 Financial Results
HOUSTON --(BUSINESS WIRE)--Nov. 9, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the third
Toggle Summary Bellicum Announces Data Presentations on Lead Product Candidate BPX-501 and CAR-T and TCR Programs at the 58th American Society of Hematology Annual Meeting
Five abstracts accepted, including oral presentation on BPX-501 Investor / analyst luncheon event on BPX-501 to be held Monday, December 5th HOUSTON --(BUSINESS WIRE)--Nov. 3, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and
Toggle Summary Bellicum and Ospedale Pediatrico Bambino Gesù Announce Expanded Collaboration to Develop Novel CAR T and TCR Cell Therapies Engineered with CaspaCIDe
CaspaCIDe-enabled CD19 CAR T cell therapy to enter clinical development in 2017 Agreement broadened after clinical successes of BPX-501 with CaspaCIDe HOUSTON & ROME --(BUSINESS WIRE)--Nov. 1, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) and Ospedale Pediatrico Bambino Gesù (OPBG), a
Toggle Summary Bellicum Pharmaceuticals to Present at Two Healthcare Investor Conferences in November
HOUSTON --(BUSINESS WIRE)--Oct. 31, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Tom Farrell, President and
Toggle Summary Bellicum Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference
HOUSTON --(BUSINESS WIRE)--Sep. 20, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Tom Farrell , President and
Toggle Summary Bellicum Pharmaceuticals to Present at the BioCentury 23rd Annual NewsMakers in the Biotech Industry Conference
HOUSTON --(BUSINESS WIRE)--Sep. 1, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Tom Farrell , President and
Toggle Summary Bellicum Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
Two INDs cleared by FDA to begin studies of controlled CAR T and TCR product candidates Conference call and webcast to be held Monday, August 8, 2016 at 5 p.m. Eastern HOUSTON --(BUSINESS WIRE)--Aug. 8, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company
Toggle Summary Bellicum Announces BPX-501 European Regulatory Updates
Company receives orphan drug designations in the European Union for BPX-501 T-cell therapy and for activator agent rimiducid Bellicum plans to pursue EU approval based on ongoing BP-004 clinical trial under “exceptional circumstances” provision HOUSTON --(BUSINESS WIRE)--Aug.
Toggle Summary Bellicum to Report Second Quarter 2016 Financial Results and Host Conference Call and Webcast on August 8, 2016
HOUSTON --(BUSINESS WIRE)--Aug. 1, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company will host a
Toggle Summary Bellicum Pharmaceuticals Announces Patent on CaspaCIDe Method for Selectively Eliminating Therapeutic Cells
Baylor College of Medicine receives patent exclusively licensed to Bellicum HOUSTON --(BUSINESS WIRE)--Jul. 20, 2016-- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan
Toggle Summary Bellicum Pharmaceuticals Enters into Research Collaboration with Leiden University Medical Center to Discover Natural High-Affinity TCRs
New collaboration builds on current license and research agreement for TCR candidates, including BPX-701 HOUSTON --(BUSINESS WIRE)--Jun. 2, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular
Toggle Summary Bellicum to Present at the Jefferies 2016 Global Healthcare Conference
HOUSTON --(BUSINESS WIRE)--Jun. 1, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Tom Farrell , President and
Toggle Summary Bellicum Announces Data Presentations at the Annual Meetings of the American Society of Clinical Oncology and the European Hematology Association
HOUSTON --(BUSINESS WIRE)--May 19, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company was selected for
Toggle Summary Bellicum Appoints Jim Daly to its Board of Directors
HOUSTON --(BUSINESS WIRE)--May 18, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of Jim Daly to
Toggle Summary Bellicum Pharmaceuticals Reports First Quarter 2016 Financial Results
HOUSTON --(BUSINESS WIRE)--May 9, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the first
Toggle Summary Bellicum to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
HOUSTON --(BUSINESS WIRE)--May 5, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced that Tom Farrell , President and CEO, is scheduled to present at the Bank of
Toggle Summary Bellicum Announces Late-Breaking Poster Presentation on TCR Product Candidate with Activation Switch at the American Association for Cancer Research (AACR) 2016 Annual Meeting
HOUSTON --(BUSINESS WIRE)--Apr. 18, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company, and its
Toggle Summary Bellicum Pharmaceuticals Announces BPX-501 Clinical Data Updates
EBMT oral presentations highlight encouraging preliminary outcomes from ongoing BP-004 clinical study in children with genetic diseases and cancers HOUSTON --(BUSINESS WIRE)--Apr. 5, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on
Toggle Summary Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for Fourth Quarter and Year Ended December 31, 2015
BPX-501 clinical data reported at ASH 2015 demonstrated disease-free outcomes in patients with genetic diseases Three novel product candidates planned to initiate Phase 1 studies in 2016 Management to host conference call and webcast today at 5 p.m. Eastern HOUSTON --(BUSINESS WIRE)--Mar.
Toggle Summary Bellicum to Present at the Barclays Global Healthcare Conference
HOUSTON --(BUSINESS WIRE)--Mar. 8, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Tom Farrell , President and
Toggle Summary Bellicum to Report Fourth Quarter and Full Year 2015 Financial Results and Host Conference Call and Webcast on March 14, 2016
HOUSTON --(BUSINESS WIRE)--Mar. 3, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, will report fourth quarter and full year 2015
Toggle Summary FDA Grants Orphan Drug Designation to Bellicum’s BPX-501 for the Treatment of Immunodeficiency and GvHD Following Stem Cell Transplant
HOUSTON --(BUSINESS WIRE)--Feb. 22, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the U.S.
Toggle Summary Bellicum Pharmaceuticals Announces Submission of BPX-701 and BPX-601 Clinical Trial Protocols for Review by the NIH RAC
HOUSTON --(BUSINESS WIRE)--Jan. 11, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced regulatory milestones and
Toggle Summary Bellicum to be Added to the NASDAQ Biotechnology Index
HOUSTON --(BUSINESS WIRE)--Dec. 14, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company has been
Toggle Summary Bellicum and Astellas Announce License Agreement for Cancer Target PSCA in Cell and Gene Therapy
Bellicum obtains rights to develop adoptive cell therapies targeting tumors expressing PSCA Astellas or Agensys retains option for commercial rights in Japan HOUSTON & TOKYO --(BUSINESS WIRE)--Dec. 11, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM, “Bellicum”) and Astellas Pharma Inc.
Toggle Summary Bellicum Announces Oral Presentation at ASH Showing Improved Potency and Control with CIDeCAR T-Cell Therapies
ASH Annual Meeting also featured poster presentations of GoCAR-T and GoTCR platforms Supporting preclinical data for CIDeCAR product candidate BPX-401 and GoCAR-T product candidate BPX-601 highlighted ORLANDO, Fla. --(BUSINESS WIRE)--Dec. 7, 2015-- Bellicum Pharmaceuticals, Inc.
Toggle Summary Bellicum Pharmaceuticals Announces BPX-501 Clinical Data Demonstrating Disease-Free Outcomes in Patients with Genetic Diseases
ASH poster presentations report on pediatric patients with beta thalassemia, SCID, Fanconi anemia, Wiskott-Aldrich Syndrome and other genetic diseases undergoing haploidentical stem cell transplant and genetically modified BPX-501 T-cell add-back No transplant-related mortality Significant
Toggle Summary Bellicum Pharmaceuticals to Participate in Fireside Chat at the Piper Jaffray 27th Annual Healthcare Conference
HOUSTON --(BUSINESS WIRE)--Nov. 24, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Tom Farrell , President and
Toggle Summary Bellicum Pharmaceuticals Reports Third Quarter 2015 Financial Results and Recent Program Updates
Pediatric patients with beta thalassemia, SCID, and Wiskott-Aldrich Syndrome are disease-free following haplo transplant with BPX-501 T cells Additional details of ongoing BPX-501 trial and adoptive T cell programs to be presented at ASH 2015 HOUSTON --(BUSINESS WIRE)--Nov.
Toggle Summary Bellicum Announces Data Presentations on Lead Product Candidate BPX-501 and CAR-T and TCR Pipeline Programs at the 57th American Society of Hematology (ASH) Annual Meeting
Seven abstracts accepted including oral presentation on the Company’s controllable CAR-T product candidate BPX-401 HOUSTON --(BUSINESS WIRE)--Nov. 5, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular
Toggle Summary Bellicum to Present at Two Healthcare Conferences in November
HOUSTON --(BUSINESS WIRE)--Nov. 2, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced that Tom Farrell , President and CEO, will present a corporate overview at two
Toggle Summary Bellicum Appoints Alan K. Smith as Senior Vice President of Manufacturing
HOUSTON --(BUSINESS WIRE)--Oct. 29, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced the appointment of Alan K. Smith , Ph.D., as Senior Vice President of
Toggle Summary Bellicum to Present at Leerink Partners Inaugural Immuno-Oncology Roundtable Conference
HOUSTON --(BUSINESS WIRE)--Sep. 28, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced that Tom Farrell , President and CEO, is scheduled to present a business overview
Toggle Summary Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Second Quarter Ended June 30, 2015
Conference call and webcast to be held Thursday, August 13, 2015 at 5 p.m. Eastern HOUSTON --(BUSINESS WIRE)--Aug. 13, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today
Toggle Summary Bellicum to Report Second Quarter 2015 Financial Results on August 13, 2015
Conference Call and Webcast to Follow at 5 p.m. Eastern HOUSTON --(BUSINESS WIRE)--Aug. 6, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, will report second quarter financial
Toggle Summary Bellicum Pharmaceuticals Announces Patent Issued on Methods for Inducing Selective Apoptosis for its Lead Product Candidate BPX-501
Baylor College of Medicine receives patent for technology exclusively licensed to Bellicum HOUSTON --(BUSINESS WIRE)--Aug. 5, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today
Toggle Summary Bellicum Pharmaceuticals to Present at the 2015 Wedbush PacGrow Healthcare Conference
HOUSTON --(BUSINESS WIRE)--Aug. 3, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced that management will present a corporate overview at the 2015 Wedbush PacGrow
Toggle Summary Bellicum Appoints Stephen R. Davis to Board of Directors
HOUSTON --(BUSINESS WIRE)--Jul. 16, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced the appointment of Stephen R. Davis to its Board of Directors. Mr.
Toggle Summary Bellicum Announces ASCO Presentation Featuring its Novel CAR T Cell Co-Stimulatory Domain Designed to Improve Potency Against Solid Tumors
“MC”-driven CIDeCARs proliferate, persist and eliminate tumors in preclinical studies CHICAGO --(BUSINESS WIRE)--May 30, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, announced
Toggle Summary Bellicum Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference
HOUSTON --(BUSINESS WIRE)--May 21, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced that management will present a corporate overview at the Jefferies 2015 Global
Toggle Summary Bellicum Announces Clinical Study Results Published in BLOOD and Featured in Late-Breaking Session at ASGCT Annual Meeting
Study shows T cells engineered with CaspaCIDe improved immune reconstitution Safety switch activation rapidly resolved GvHD symptoms HOUSTON --(BUSINESS WIRE)--May 14, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and
Toggle Summary Bellicum Pharmaceuticals Reports First Quarter 2015 Financial Results
HOUSTON --(BUSINESS WIRE)--May 11, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today reported financial results for the first quarter of 2015, and provided an update on the
Toggle Summary Bellicum Pharmaceuticals Leases Space for Pilot Manufacturing Facility
HOUSTON --(BUSINESS WIRE)--May 8, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced that it has entered into a lease agreement to enable in-house cell therapy
Toggle Summary Bellicum Pharmaceuticals Licenses TCR Technology From Leiden University Medical Center
Lead TCR candidate targeting solid tumors to begin clinical studies in 2015 HOUSTON --(BUSINESS WIRE)--Apr. 29, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced it
Toggle Summary Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for Fourth Quarter and Year Ended December 31, 2014
Management to host webcast and conference call today at 5 p.m. Eastern HOUSTON --(BUSINESS WIRE)--Mar. 11, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today reported financial
Toggle Summary Bellicum to Report Fourth Quarter and Full Year 2014 Financial Results on March 11, 2015
Conference Call and Webcast to Follow at 5 p.m. Eastern HOUSTON --(BUSINESS WIRE)--Mar. 4, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, will report fourth quarter and year-end
Toggle Summary Bellicum Pharmaceuticals to Present at the 2015 Leerink Global Healthcare Conference
HOUSTON --(BUSINESS WIRE)--Feb. 4, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced that management will present at the 2015 Leerink Global Healthcare Conference at
Toggle Summary Bellicum Pharmaceuticals Announces Successful Dosing of First Patient Cohort With BPX-501 T Cells Following Haplo-Identical Hematopoietic Stem Cell Transplant
BPX-501 is being evaluated as adjunct T cell therapy in patients with hematologic cancers and genetic blood diseases who lack a matched donor HOUSTON --(BUSINESS WIRE)--Jan. 13, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering
Toggle Summary Bellicum Pharmaceuticals Announces Closing of Initial Public Offering and Exercise of the Underwriters’ Option
HOUSTON --(BUSINESS WIRE)--Dec. 23, 2014-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced the closing of its underwritten initial public offering of common stock, including the
Toggle Summary Bellicum Pharmaceuticals Prices Initial Public Offering of 7,350,000 Shares of Common Stock
HOUSTON --(BUSINESS WIRE)--Dec. 18, 2014-- Bellicum Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced the pricing of its initial public offering of 7,350,000 shares of its common stock, an increase of 1,100,000
Toggle Summary Bellicum Announces New Director, Executive Management Appointments
Houston, TX, December 5, 2014 – Bellicum Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced the appointment of a new Director and two senior executives to its management team.  Jon P.
Toggle Summary Bellicum Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
Houston, TX, November 18, 2014 – Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced it has filed a registration statement on Form S-1 with the U.S.
Toggle Summary Bellicum Appoints Reid Huber, Ph.D. to Board of Directors
Houston, TX, November 17, 2014  –Bellicum Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced the appointment of Reid M. Huber, Ph.D. to its Board of Directors. Dr.
Toggle Summary ARIAD and Bellicum Announce Revised License Agreement for ARIAD’s Cell-Signaling Technology
Cambridge, MA, and Houston, TX, October 6, 2014 – ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Bellicum Pharmaceuticals, Inc. today announced a restructuring of their license agreement for ARIAD’s cell-signaling technology. ARIAD will receive $50 million in exchange for a fully paid up license to
Toggle Summary Bellicum Pharmaceuticals Secures $55 Million in Oversubscribed Series C Financing
Investor syndicate includes leading biotech and mutual funds Houston, TX, August 27, 2014 – Bellicum Pharmaceuticals, Inc., a biotechnology company focused on developing safer and more effective cellular immunotherapies, today announced the successful completion of a $55M Series C financing.
Toggle Summary Bellicum Pharmaceuticals to Present at Jefferies 2014 Global Healthcare Conference In New York City
New York, NY – June 3, 2014 – Bellicum Pharmaceuticals, Inc. announced today that Tom Farrell, Chief Executive Officer, will provide an update on the Company at the Jefferies 2014 Global Healthcare Conference in New York City. The presentation will take place today, Tuesday, June 3 from 9:00-9:30
Toggle Summary First Cancer Trial Launched Using CAR T Cells Engineered with Bellicum’s Safety Switch
NCI study to investigate whether third generation CAR T Cells can be eliminated if they become harmful Bellicum's CaspaCIDe ® safety switch is designed to enable more cancers to be safely treated with CAR T cells Houston, TX – March 17, 2014 – Bellicum Pharmaceuticals, Inc.
Toggle Summary Bellicum Pharmaceuticals Raises $34.4 Million in a Series B Financing
Funds Will Expand Clinical Development of Company's Controlled Cellular Immunotherapies Houston, TX – January 7, 2014 – Bellicum Pharmaceuticals, Inc. announced today that it has completed a second and final closing of its Series B financing, securing an additional $14.7 million and bringing the
Toggle Summary Bellicum Pharmaceuticals Initiates Clinical Trial with Novel Controlled Dendritic Cell Immunotherapy in Metastatic Castrate Resistant Prostate Cancer
Houston, TX, July 9, 2013 – Bellicum Pharmaceuticals, Inc. announced today it has initiated treatment of the first patient in a study of BPX-201 dendritic cells in combination with activating agent AP1903. The Phase I dose escalation trial in patients with metastatic castrate resistant prostate
Toggle Summary Bellicum Appoints Baylor College of Medicine’s David M. Spencer as Chief Scientific Officer
Houston, TX, April 12, 2012 – Bellicum Pharmaceuticals, Inc. announced today the appointment of David M. Spencer, Ph.D. to Chief Scientific Officer. Dr. Spencer, a co-founder of Bellicum, joins the Company from Baylor College of Medicine where he was Vice Chairman of Pathology and Immunology. Dr.
Toggle Summary Bellicum Closes $20 Million Series B Financing
Funding Supports Two Programs Through Phase 2 Development Houston, TX, March 8, 2012 – Bellicum Pharmaceuticals, Inc. today announced that it has raised $20 million in a Series B financing. The funding will be used to advance its lead CaspaCIDe™ and DeCIDe™ programs through Phase 2 clinical
Toggle Summary Bellicum Announces Publication in The New England Journal of Medicine Demonstrating Complete Reversal of Serious Immune Condition in Hematopoietic Stem Cell Transplant Patients
Broad Applicability of Genetic "Safety Switch" for Improving Cell Therapy Outcomes Houston, TX, November 2, 2011 – Bellicum Pharmaceuticals, Inc. today announced publication in The New England Journal of Medicine of clinical results using a new therapy that demonstrated rapid and complete reversal
Toggle Summary Bellicum Pharmaceuticals Awarded $5.7 Million by the Cancer Prevention and Research Institute of Texas
Award to Support Clinical Trials and Additional Personnel Houston, TX, March 25, 2011 – Bellicum Pharmaceuticals, Inc. today announced that the Company received notice of a $5.7 million company commercialization award from the Cancer Prevention and Research Institute of Texas (“CPRIT”).
Toggle Summary Journal of Clinical Investigation Publishes Data Demonstrating Enhanced Antitumor Efficacy of Second Generation DeCIDe™ Technology
Houston, TX, March 8, 2011 – Bellicum Pharmaceuticals, Inc. today announced the publication of studies comparing AP1903-activated iMyD88/CD40-transduced dendritic cells (DCs) to conventionally matured DCs, in the April 2011 issue of The Journal of Clinical Investigation (JCI).
Toggle Summary Clinical Responses Demonstrated in Metastatic Castrate Resistant Prostate Cancer Patients Treated with BPX-101 Cancer Vaccine
Phase I/II Results Presented at 2011 Genitourinary Cancers Symposium Orlando, FL, February 18, 2011 – Bellicum Pharmaceuticals, Inc. today announced the presentation of Phase I/II safety and efficacy data for BPX-101, a novel drug-activated dendritic cell vaccine for metastatic castrate resistant
Toggle Summary Bellicum Pharmaceuticals Announces $3 Million in Convertible Note Funding
Houston, TX, December 21, 2010 – Bellicum Pharmaceuticals, Inc. today announced $3 million in Convertible Note funding. The new funds will be used to prepare for Phase II trials of BPX-101, the company’s DeCIDe™ vaccine for metastatic castrate resistant prostate cancer (mCRPC), and CaspaCIDe™, a
Toggle Summary Bellicum Pharmaceuticals Announces World Renowned Clinical Advisory Board Appointments
Company Launches New Website Highlighting Breadth of Clinical Pipeline Houston, TX, November 10, 2010 – Bellicum Pharmaceuticals, Inc., a company developing novel therapies that can be precisely controlled after delivery, today announced the appointment of four new members to its Clinical Advisory
Toggle Summary Systemic and Antigen-Specific Immune Responses in Patients Treated with Cancer Vaccine BPX-101 Correlate with Clinical Response
Interim Phase I/II Results Presented at AACR 2010 Annual Meeting Houston, TX, April 19, 2010 – Bellicum Pharmaceuticals, Inc., a company developing therapeutic cancer vaccines, today announced the presentation of interim Phase I/II efficacy data for BPX-101, a novel dendritic cell vaccine for
Toggle Summary Bellicum Pharmaceuticals Announces $4.5 Million in New Funding
Houston, TX, October 27, 2009 – Bellicum Pharmaceuticals, Inc. today announced $4.5 million in Series A and Convertible Note funding. The new funds will be used to complete the company’s ongoing Phase I/IIa trial of BP-GMAX-CD1 in patients with advanced, androgen independent prostate cancer, and to
Toggle Summary Bellicum Pharmaceuticals Announces Initiation of Phase I-II Clinical Trial of Novel Vaccine for Patients with Advanced Prostate Cancer
Houston, TX, August 9, 2009 – Bellicum Pharmaceuticals, Inc. today announced dosing of the first patient in a Phase I/II clinical trial of BP-GMAX-CD1, a novel pharmacologically regulated dendritic cell vaccine for the treatment of prostate cancer. The disease-specific trial is being conducted
Toggle Summary Bellicum Pharmaceuticals Announces $3.75 Million in Financing
Houston, TX, October 9, 2007 – Bellicum Pharmaceuticals, Inc. today announced it was awarded $1.45 Million by the State of Texas’ Emerging Technology Fund. Additionally, the company announced seed financing of $2.3 million. The combined investment will be used for development of the company’s lead
Toggle Summary Bellicum Pharmaceuticals Announces Commercial Licensing of Ariad’s Argent™ Cell-Signaling Regulation Technology for Development of New Cancer Therapies
Baylor College of Medicine Spin-out Company Focuses on Therapeutic Vaccines for the Treatment of Cancer Houston, TX, October 11, 2006 – Bellicum Pharmaceuticals, Inc. has announced a non-exclusive, royalty-bearing licensing agreement with ARIAD Pharmaceuticals Inc.